• An independent Drug Information & Research Center (DIRC) registered with International Registry of Drug Information Service (IRDIS)
  • It has been providing unbiased drug information to healthcare professionals including Students and professional pharmacists and the medical practitioners
  • The highlight of this service is that even the lay public too has been seeking information on various aspects of medication and to sort out their doubts and confusion
  • The DIRC is communicating the vital information on medicines through SMS, Facebook and through email to the Registered Pharmacists

DIRC Newsletter

KSPC released the first issue of DIC Newsletter in October 1999. The eight-page bulletin carries information on the activities of drug information & rationale use of drugs, commonly asked enquiries and invited articles from experts from healthcare—specifically pharmaceutical domain. The bulletin is designed for local use within the pharmacy and medical community. One page in every issue is dedicated to articles in Kannada. The DIC newsletter is a member of International Society of Drug Bulletins (ISDB)

Read More

How to avail the Drug information services?

  • Pass on your queries either over phone (080-46729800 (100 line)/ 23383142 / 23404000) extn:7/8 or by mail: or by post / courier to office address with your contact details
  • The DIRC pharmacist will call you back for any additional information required and the Drug information will be passed on to you by e-mail / telecon

This service is provided free of cost to the doctors, pharmacists, students, patients and the general public

Books and Reference Guides


Drug of the Season - Remdesivir

Remdesivir is indicated for adults and pediatric patients (12 years of age or older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization. Remdesivir should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.

Read More

Drug Safety Alerts - Pharmacovigilance Programme of India (PvPI)

The preliminary analysis of Serious Unexpected Serious Adverse Reaction (SUSARs) from the PvPI database reveals that the following drugs are associated with the risks as given below.

Read More

News and Events

Contact Us


Mobile No.

E-mail ID